Top

Diabetologia

Published in:

01-01-2007 | Article

Increased blood–brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases

Authors: B. T. Hawkins, T. F. Lundeen, K. M. Norwood, H. L. Brooks, R. D. Egleton

Published in: Diabetologia | Issue 1/2007

Abstract

Aims/hypothesis

Although diabetes mellitus is associated with peripheral microvascular complications and increased risk of neurological events, the mechanisms by which diabetes disrupts the blood–brain barrier (BBB) are not known. Matrix metalloproteinase (MMP) activity is increased in diabetic patients, is associated with degradation of tight junction proteins, and is a known mediator of BBB compromise. We hypothesise that diabetes leads to compromise of BBB tight junctions via stimulation of MMP activity.

Materials and methods

Diabetes was induced in the rat with streptozotocin. At 14 days after injection, BBB function was assessed by in situ brain perfusion. Tight junction proteins were assessed by immunoblot and immunofluorescence. Plasma MMP activity was quantified by fluorometric gelatinase assay and gel zymography.

Results

In streptozotocin-treated animals, permeability to [¹⁴C]sucrose increased concurrently with decreased production of BBB tight junction proteins occludin (also known as OCLN) and zona occludens 1 (ZO-1, also known as tight junction protein 1 or TJP1). Insulin treatment, begun on day 7, normalised blood glucose levels and attenuated BBB hyperpermeability to [¹⁴C]sucrose. Neither acute hyperglycaemia in naive animals nor acute normalisation of blood glucose in streptozotocin-treated animals altered BBB permeability to [¹⁴C]sucrose. Plasma MMP activity was increased in streptozotocin-treated animals.

Conclusions/interpretation

These data indicate that diabetes increases BBB permeability via a loss of tight junction proteins, and that increased BBB permeability in diabetes does not result from hyperglycaemia alone. Increased plasma MMP activity is implicated in degradation of BBB tight junction proteins and increased BBB permeability in diabetes. Peripheral MMP activity may present a novel target for protection of the BBB and prevention of neurological complications in diabetes.

Available only for authorised users

Hawkins BT, Davis TP (2005) The blood–brain barrier/neurovascular unit in health and disease. Pharm Rev 57:173–185PubMedCrossRef

Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279–2299PubMedCrossRef

Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD (2005) Matrix metalloproteinases and diabetic vascular complications. Angiology 56:173–189PubMedCrossRef

Ristow M (2004) Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 82:510–529PubMedCrossRef

Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64–74PubMedCrossRef

Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I (2003) Increased blood–brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 74:70–76PubMedCrossRef

Iwata A, Koike F, Arasaki K, Tamaki M (1999) Blood brain barrier destruction in hyperglycemic chorea in a patient with poorly controlled diabetes. J Neurol Sci 163:90–93PubMedCrossRef

Hovsepyan MR, Haas MJ, Boyajyan AS et al (2004) Astrocytic and neuronal biochemical markers in the sera of subjects with diabetes mellitus. Neurosci Lett 369:224–227PubMedCrossRef

Mooradian AD, Haas MJ, Batejko O, Hovsepyan M, Feman SS (2005) Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes 54:2977–2982PubMed

10.

Dai J, Vrensen GF, Schlingemann RO (2002) Blood–brain barrier integrity is unaltered in human brain cortex with diabetes mellitus. Brain Res 954:311–316PubMedCrossRef

11.

Rechthand E, Smith QR, Latker CH, Rapoport SI (1987) Altered blood–nerve barrier permeability to small molecules in experimental diabetes mellitus. J Neuropathol Exp Neurol 46:302–314PubMed

12.

Ennis SR, Betz AL (1986) Sucrose permeability of the blood–retinal and blood–brain barriers. Effects of diabetes, hypertonicity, and iodate. Invest Ophthalmol Vis Sci 27:1095–1102PubMed

13.

Chehade JM, Haas MJ, Mooradian AD (2002) Diabetes-related changes in rat cerebral occludin and zonula occludens-1 (ZO-1) expression. Neurochem Res 27:249–252PubMedCrossRef

14.

Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW (1998) Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 47:1953–1959PubMed

15.

Giebel SJ, Menicucci G, McGuire PG, Das A (2005) Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood–retinal barrier. Lab Invest 85:597–607PubMedCrossRef

16.

Derosa G, Avanzini MA, Geroldi D et al (2005) Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract 70:119–125PubMedCrossRef

17.

Signorelli SS, Malaponte G, Libra M et al (2005) Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med 10:1–6PubMedCrossRef

18.

Rosenberg GA, Estrada EY, Dencoff JE (1998) Matrix metalloproteinases and TIMPs are associated with blood–brain barrier opening after reperfusion in rat brain. Stroke 29:2189–2195PubMed

19.

Mun-Bryce S, Rosenberg GA (1998) Gelatinase B modulates selective opening of the blood–brain barrier during inflammation. Am J Physiol 274:R1203–R1211PubMed

20.

Wachtel M, Frei K, Ehler E, Fontana A, Winterhalter K, Gloor SM (1999) Occludin proteolysis and increased permeability in endothelial cells through tyrosine phosphatase inhibition. J Cell Sci 112( Pt 23):4347–4356PubMed

21.

Williams SA, Abbruscato TJ, Hruby VJ, Davis TP (1996) Passage of a delta-opioid receptor selective enkephalin, [d-penicillamine2,5] enkephalin, across the blood–brain and the blood–cerebrospinal fluid barriers. J Neurochem 66:1289–1299PubMedCrossRef

22.

Hawkins BT, Abbruscato TJ, Egleton RD et al (2004) Nicotine increases in vivo blood–brain barrier permeability and alters cerebral microvascular tight junction protein distribution. Brain Res 1027:48–58PubMedCrossRef

23.

Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365–386PubMed

24.

McReynolds MR, Taylor-Garcia KM, Greer KA, Hoying JB, Brooks HL (2005) Renal medullary gene expression in aquaporin-1 null mice. Am J Physiol Renal Physiol 288:F315–F321PubMedCrossRef

25.

Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, New York

26.

Willis CL, Leach L, Clarke GJ, Nolan CC, Ray DE (2004) Reversible disruption of tight junction complexes in the rat blood–brain barrier, following transitory focal astrocyte loss. Glia 48:1–13PubMedCrossRef

27.

Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH (2000) Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20:1681–1689PubMedCrossRef

28.

Hawkins BT, Egleton RD, Davis TP (2005) Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. Am J Physiol, Heart Circ Physiol 289:H212–H219CrossRef

29.

Wang FQ, So J, Reierstad S, Fishman DA (2005) Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 114:19–31PubMedCrossRef

30.

Like AA, Rossini AA (1976) Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193:415–417PubMedCrossRef

31.

Rakieten N, Rakieten ML, Nadkarni MR (1963) Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 29:91–98

32.

Winer N, Sowers JR (2004) Epidemiology of diabetes. J Clin Pharmacol 44:397–405PubMedCrossRef

33.

Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK (1990) Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263:2893–2898PubMedCrossRef

34.

Bickel U (2005) How to measure drug transport across the blood–brain barrier. NeuroRx 2:15–26PubMedCrossRef

35.

Preston JE, al-Sarraf H, Segal MB (1995) Permeability of the developing blood–brain barrier to 14C-mannitol using the rat in situ brain perfusion technique. Brain Res Dev Brain Res 87:69–76PubMedCrossRef

36.

Witt KA, Mark KS, Hom S, Davis TP (2003) Effects of hypoxia-reoxygenation on rat blood–brain barrier permeability and tight junctional protein expression. Am J Physiol, Heart Circ Physiol 285:H2820–H2831

37.

Maepea O, Karlsson C, Alm A (1984) Blood–ocular and blood–brain barrier function in streptozocin-induced diabetes in rats. Arch Ophthalmol 102:1366–1369PubMed

38.

Lorenzi M, Healy DP, Hawkins R, Printz JM, Printz MP (1986) Studies on the permeability of the blood–brain barrier in experimental diabetes. Diabetologia 29:58–62PubMedCrossRef

39.

Hawkins BT, Fleegal MA, McCaffery G, Egleton RD (2006) Contributions of hyperglycaemia and gelatinase activity to increased blood–brain barrier permeability in experimental diabetes. Society for Neuroscience, Annual Meeting (Abstract)

40.

Bazzoni G, Dejana E (2004) Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 84:869–901PubMedCrossRef

41.

Penes MC, Li X, Nagy JI (2005) Expression of zonula occludens-1 (ZO-1) and the transcription factor ZO-1-associated nucleic acid-binding protein (ZONAB)-MsY3 in glial cells and colocalization at oligodendrocyte and astrocyte gap junctions in mouse brain. Eur J Neurosci 22:404–418PubMedCrossRef

42.

Harkness KA, Adamson P, Sussman JD, Davies-Jones GA, Greenwood J, Woodroofe MN (2000) Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 123:698–709PubMedCrossRef

43.

Jacqueminet S, Ben Abdesselam O, Chapman MJ et al (2006) Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 367:103–107PubMedCrossRef

44.

Nguyen JH, Yamamoto S, Steers J et al (2005) Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice. J Hepatol 44:1105–1114PubMedCrossRef

45.

Nakaya R, Uzui H, Shimizu H et al (2005) Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int J Cardiol 105:67–73PubMedCrossRef

46.

Nomura S, Yoshimura K, Akiyama N et al (2005) HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins. Eur Surg Res 37:370–378PubMedCrossRef

47.

Couture R, Harrisson M, Vianna RM, Cloutier F (2001) Kinin receptors in pain and inflammation. Eur J Pharmacol 429:161–176PubMedCrossRef

48.

Huber JD, Hau VS, Borg L, Campos CR, Egleton RD, Davis TP (2002) Blood–brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain. Am J Physiol, Heart Circ Physiol 283:H1531–H1537

49.

Banks WA, Jaspan JB, Kastin AJ (1997) Effect of diabetes mellitus on the permeability of the blood–brain barrier to insulin. Peptides 18:1577–1584PubMedCrossRef

50.

Mooradian AD (1987) Blood–brain barrier choline transport is reduced in diabetic rats. Diabetes 36:1094–1097PubMed

Title: Increased blood–brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases
Authors: B. T. Hawkins
T. F. Lundeen
K. M. Norwood
H. L. Brooks
R. D. Egleton
Publication date: 01-01-2007
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 1/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0485-z

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Increased blood–brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 1/2007

Relationships of maternal and paternal birthweights to features of the metabolic syndrome in adult offspring: an inter-generational study in South India

Comment on: Brugman S et al. (2006) Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 49:2105–2108

TCF7L2: the biggest story in diabetes genetics since HLA?

The effects of acute hypoglycaemia on memory acquisition and recall and prospective memory in type 1 diabetes

Amelioration of glucose tolerance by hepatic inhibition of nuclear factor κB in db/db mice

Enhanced mitochondrial metabolism may account for the adaptation to insulin resistance in islets from C57BL/6J mice fed a high-fat diet

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page